Ocera Therapeutics

About

Ocera Therapeutics is a biopharmaceutical company developing novel therapeutics for patients with acute and chronic liver diseases.

Palo Alto,California,United States
11 - 50

Highlights

Details

Last Funding Type: Series C
Last Funding Money Raised: $35.50M
Industries: Biopharma,Biotechnology,Therapeutics
Founded date: Jan 1, 2005
Number Of Employee: 11 - 50
Operating Status: Active
Stock Symbol: nasdaq:OCRX
Legal Name: Ocera Therapeutics, Inc.
Also Known As: TRANZYME INC.,Renovia Inc

Ocera is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need.

Ocera's HE clinical development efforts include a recently completed Phase 2b clinical trial, STOP-HE, which evaluated the safety and efficacy of intravenously-administered OCR-002 in resolving neurocognitive symptoms of acute HE in hospitalized patients with elevated ammonia. Ocera is preparing to meet with the FDA later this year to review the IV program and discuss potential development paths forward.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

6

$151M

Ocera Therapeutics has raised a total of $151M in funding over 2 rounds. Their latest funding was raised on Aug 3, 2015 from a Post-IPO Debt round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Aug 3, 2015	Post-IPO Debt	$20M	3	—	—	Detail
Nov 6, 2013	Post-IPO Equity	$28M	8	—	—	Detail
Mar 30, 2012	Post-IPO Debt	$1.50M	—	—	—	Detail
Apr 4, 2011	IPO	$54M	—	—	—	Detail
Feb 20, 2008	Series C	$35.50M	9	Greenspring Associates	—	Detail

Investors

Number of Lead Investors

Number of Investors

2

20

Ocera Therapeutics is funded by 20 investors. Sofinnova Investments and Greenspring Associates are the most recent investors.

Investor Name	Lead Investor	Funding Round
Sofinnova Investments	Yes	Series B
Greenspring Associates	—	Post-IPO Debt
Oxford Finance LLC	—	Post-IPO Debt
Silicon Valley Bank	—	Post-IPO Debt
Deerfield Partners	—	Post-IPO Equity
Great Point Partners	—	Post-IPO Equity
InterWest Partners	—	Post-IPO Equity
QVT Financial	—	Post-IPO Equity
RA Capital Management	—	Post-IPO Equity
Three Arch Partners	—	Post-IPO Equity